A clinical trial to study the effect of eyedrops prepared from umbilical cord blood in healing of epithelial defect of the corneal graft after transplantatio
Phase 2
Completed
- Conditions
- Health Condition 1: null- Post keratoplasty epithelial defect
- Registration Number
- CTRI/2014/01/004361
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 105
Inclusion Criteria
1.Operated optical keratoplasty (either penetrating keratoplasty or anterior lamellar keratoplasty).
2. Epithelial defect more than 2 mm2 on first post-operative day.
3. Patients giving consent
4.Cooperative for digital photography
Exclusion Criteria
1.Active ocular or lid infections
2.Lid abnormalities contributory to the epithelial defect
3.Severe dry eye
4.Limbal stem cell deficiency
5.Elevated IOP
6.Impending perforation
7.Pregnant and lactating women
8.Not giving consent
9.Not motivated for follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms in umbilical cord serum promote corneal graft re-epithelialization in post-keratoplasty defects?
How does umbilical cord blood therapy compare to amniotic membrane grafts for corneal epithelial healing after transplantation?
Which biomarkers correlate with successful re-epithelialization in CTRI/2014/01/004361 corneal graft trials using cord serum?
What are the potential adverse events of autologous umbilical cord serum eyedrops in post-transplant corneal epithelial defect management?
Are there synergistic effects when combining umbilical cord serum with anti-inflammatory agents for corneal graft healing in Phase II trials?